Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series
Jasmin Heidepriem,Christine Dahlke,Robin Kobbe,René Santer,Till Koch,Anahita Fathi,Bruna M S Seco,My L Ly,Stefan Schmiedel,Dorothee Schwinge,Sonia Serna,Katrin Sellrie,Niels-Christian Reichardt,Peter H Seeberger,Marylyn M Addo,Felix F Loeffler,On Behalf Of The Id-Uke Covid-Study Group,Bruna Seco,My Ly,Peter Seeberger,Marylyn Addo,Felix Loeffler,
DOI: https://doi.org/10.3390/pathogens10040438
IF: 3.7
2021-04-06
Pathogens
Abstract:The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A better understanding of its immunogenicity can be important for the development of improved diagnostics, therapeutics, and vaccines. Here, we report the longitudinal analysis of three COVID-19 patients with moderate (#1) and mild disease (#2 and #3). Antibody serum responses were analyzed using spike glycoprotein enzyme linked immunosorbent assay (ELISA), full-proteome peptide, and glycan microarrays. ELISA immunoglobulin A, G, and M (IgA, IgG, and IgM) signals increased over time for individuals #1 and #2, whereas #3 only showed no clear positive IgG and IgM result. In contrast, peptide microarrays showed increasing IgA/G signal intensity and epitope spread only in the moderate patient #1 over time, whereas early but transient IgA and stable IgG responses were observed in the two mild cases #2 and #3. Glycan arrays showed an interaction of antibodies to fragments of high-mannose and core N-glycans, present on the viral shield. In contrast to protein ELISA, microarrays allow for a deeper understanding of IgA, IgG, and IgM antibody responses to specific epitopes of the whole proteome and glycans of SARS-CoV-2 in parallel. In the future, this may help to better understand and to monitor vaccination programs and monoclonal antibodies as therapeutics.
microbiology